Antithrombotic therapy for heart failure in sinus rhythm

Fundamental and Clinical Pharmacology

Volumn 23, Issue 6, 2009, Pages 705-717

  Subramaniam, Veeran ^a   Davis, Russell C ^a   Shantsila, Eduard ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

Antiplatelet agents; Antithrombotic therapy; Heart failure; Thromboembolism

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; CLOPIDOGREL; DICOUMAROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; LISINOPRIL; PERINDOPRIL; PLACEBO; WARFARIN;

ANTICOAGULANT THERAPY; ARTERY EMBOLISM; ARTERY THROMBOSIS; ARTIFICIAL EMBOLISM; BLEEDING; BRAIN HEMORRHAGE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE CARDIOMYOPATHY; DRUG WITHDRAWAL; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART VENTRICLE FUNCTION; HEART VENTRICLE THROMBOSIS; HOSPITALIZATION; HUMAN; LUNG EMBOLISM; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PRIORITY JOURNAL; REVIEW; SINUS RHYTHM; STROKE; SYSTOLIC DYSFUNCTION; THROMBOEMBOLISM; THROMBOGENESIS; THROMBOSIS PREVENTION;

ANTICOAGULANTS; ATRIAL FIBRILLATION; CHRONIC DISEASE; FIBRINOLYTIC AGENTS; HEART FAILURE; HUMANS; PLATELET AGGREGATION INHIBITORS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SINOATRIAL NODE; THROMBOEMBOLISM;

EID: 70449475854     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00776.x     Document Type: Review

References (113)

1. Levy W.C., Mozaffarian D., Linker D.T. The Seattle Heart Failure Model: prediction of survival in heart failure. Circulation (2006) 113 1424 1433.
2. Stewart S., Jenkins A., Buchan S., McGuire A., Capewell S., McMurray J.J. The current cost of heart failure to the Nation al Health Service in the UK. Eur J Heart Fail (2002) 3 361 371.
3. Abraham W.T., Fonarow G.C., Albert N.M. et al. Predictors of in-hospital mortality in patients hospitalized for heart failure: insights from the Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF). J. Am. Coll. Cardiol. (2008) 52 347 356.
4. Cleland J.G.F., Daubert J.C., Erdmann E. et al. Cardiac Resynchronization-Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N. Engl. J. Med. (2005) 352 1539 1549.
5. Lip G.Y.H., Gibbs C.R. Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm: a Cochrane systematic review. QJM (2002) 95 461 468.
6. Witt B.J., Gami A.S., Ballman K.V. et al. The incidence of ischemic stroke in chronic heart failure: a meta-analysis. J. Card. Fail. (2007) 13 489 496.
7. Witt B.J., Brown R.D. Jr., Jacobsen S.J. et al. Ischemic stroke after heart failure: a community-based study. Am. Heart J. (2006) 152 102 109.
8. Mujib M., Giamouzis G., Agha S.A. et al. Epidemiology of stroke in chronic heart failure patients with normal sinus rhythm: findings from the DIG stroke sub-study. Int. J. Cardiol. (2009) [Epub ahead of print].
9. Grigorian-Shamagian L., Otero Raviña F., Abu Assi E. et al. Why and when do patients with heart failure and normal left ventricular ejection fraction die? Analysis of >600 deaths in a community long-term study. Am. Heart J. (2008) 156 1184 1190.
10. Wolf P.A., Kannel W.B., McNamara P.M. Occult impaired cardiac function, chronic heart failure and risk of thrombotic stroke: the Framingham Study. Neurology (1970) 20 373.
11. Isnard R., Komajda M. Thromboembolism in heart failure, old ideas and new challenges. Eur. J. Heart Fail. (2001) 2 265 269.
12. Hays A.G., Sacco R.L., Rundek T. et al. Left ventricular systolic dysfunction and the risk of ischemic stroke in a multiethnic population. Stroke (2006) 37 1715 1719.
13. Siachos T., Vanbakel A., Feldman D.S., Uber W., Simpson K.N., Pereira N.L. Silent strokes in patients with heart failure. J. Card. Fail. (2005) 11 485 489.
14. Petty G.W., Brown R.D. Jr., Whisnant J.P., Sicks J.D., O'Fallon W.M., Wiebers D.O. Survival and recurrence after first cerebral infarction: a population-based study in Rochester, Minnesota, 1975 through 1989. Neurology (1998) 50 208 216.
15. Kannel W.B., Wolf P.A., Verter J. Manifestations of coronary disease predisposing to stroke. The Framingham Study. JAMA (1983) 250 2942 2946.
16. Fuster V., Gersh B.J., Giuliani E.R., Tajik A.J., Brandenbury R.O., Frye R.L. The natural history of idiopathic dilated cardiomyopathy. Am. J. Cardiol. (1981) 47 525 531.
17. Falk R.H., Foster E., Coats M.H. Ventricular thrombi and thromboembolism in dilated cardiomyopathy: a prospective. Am. Heart J. (1992) 123 136 142.
18. Katz S.D., Marantz P.R., Biasucci L. et al. Low incidence of stroke in ambulatory patients with heart failure: a prospective study. Am. Heart J. (1993) 126 141 146.
19. Natterson P.D., Stevenson W.G., Saxon L.A., Middlekauff H.R., Stevenson L.W. Risk of arterial embolization in 224 patients awaiting cardiac transplantation. Am. Heart J. (1995) 129 564 570.
20. Cioffi G., Pozzoli M., Forni G. et al. Systemic thromboembolism in chronic heart failure. A prospective study in 406 patients. Eur. Heart J. (1996) 17 1381 1389.
21. Ciaccheri M., Castelli G., Cecchi F. et al. Lack of correlation between intracavitary thrombosis detected by cross sectional echocardiography and systemic emboli in patients with dilated cardiomyopathy. Br Heart J. (1989) 62 26 29.
22. Sharma N.D., McCullough P.A., Philbin E.F., Weaver W.D. Left ventricular thrombus and subsequent thromboembolism in patients with severe systolic dysfunction. Chest (2000) 117 314 320.
23. Gottdiener J.S., Gay J.A., VanVoorhees L., DiBianco R., Fletcher R.D. Frequency and embolic potential of left ventricular thrombus in dilated cardiomyopathy: assessment by 2-dimensional echocardiography. Am. J. Cardiol. (1983) 52 1281 1285.
24. Diaz R.A., Obasohan A., Oakley C.M. Prediction of outcome in dilated cardiomyopathy. Br Heart J. (1987) 58 393 399.
25. Blondheim D.S., Jacobs L.E., Kotler M.N., Costacurta G.A., Parry W.R. Dilated cardiomyopathy with mitral regurgitation: decreased survival despite a low frequency of left ventricular thrombus. Am. Heart J. (1991) 122 763 771.
26. Chung I., Lip G.Y.H. Antithrombotic therapy for chronic heart failure. Int. J. Clin. Pract. (2006) 60 36 47.
27. Ahnert A.M., Freudenberger R.S. What do we know about anticoagulation in patients with heart failure? Curr. Opin. Cardiol. (2008) 23 228 232.
28. Dries D.L., Rosenberg Y.D., Waclawiw M.A., Domanski M.J. Ejection fraction and risk of thromboembolic events in patients with systolic dysfunction and sinus rhythm: evidence for gender differences in the studies of left ventricular dysfunction trials. J. Am. Coll. Cardiol. (1997) 29 1074 1080.
29. Loh E., Sutton M.S., Wun C.C. et al. Ventricular dysfunction and the risk of stroke after myocardial infarction. N. Engl. J. Med. (1997) 336 251 257.
30. Dunkman W.B., Johnson G.R., Carson P.E., Bhag G., Farrell L., Cohn J.N. Incidence of thromboembolic events in chronic heart failure. Circulation 1993) 87 (Suppl. 6) 94 101.
31. Falk R.H., Pollak A., Tandon P.K., Packer M. The effect of warfarin on prevalence of stroke in patients with severe heart failure. J. Am. Coll. Cardiol. (1993) 21 218. (Abstract).
32. Freudenberger R.S., Hellkamp A.S., Halperin J.L. et al. Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation (2007) 115 2637 2641.
33. Roberts W.C., Siegel R.J., McManus B.M. Idiopathic dilated cardiomyopathy, analysis of 152 necropsy patients. Am. J. Cardiol. (1987) 60 1340 1355.
34. Uretsky B.F., Thygesen K., Armstrong P.W. et al. Acute coronary findings at autopsy in heart failure patients with sudden death: results from the assessment of treatment with lisinopril and survival (ATLAS) trial. Circulation (2000) 102 611 616.
35. Steveson W.G., Steveson L.W., Midlekauff H.R., Saxon L.A. Sudden death prevention in patients with advanced ventricular dysfunction. Circulation (1993) 33 1424 1426.
36. Cleland J.G.F. Anticoagulant and anti-platelet therapy in heart failure. Curr. Opin. Cardiol. (1997) 12 276 287.
37. Fuster V., Halperin J.L. Left ventricular thrombi and cerebral embolism. N. Engl. J. Med. (1989) 320 392 394.
38. Lip G.Y.H., Gibbs C.R. Does heart failure confers: a Hypercoagulable state? Virchow's Triad Revisited. J. Am. Coll. Cardiol. (1999) 33 1424 1426.
39. Bennett P.C., Silverman S.H., Gill P.S., Lip G.Y. Peripheral arterial disease and Virchow's triad. Thromb. Haemost. (2009) 101 1032 1040.
40. Strijbos M.H., Rao C., Schmitz P.I. et al. Correlation between circulating endothelial cell counts and plasma thrombomodulin levels as markers for endothelial damage. Thromb. Haemost. (2008) 100 642 647.
41. Makin A.J., Blann A.D., Chung N.A., Silverman S.H., Lip G.Y. Assessment of endothelial damage in atherosclerotic vascular disease by quantification of circulating endothelial cells. Relationship with von Willebrand factor and tissue factor. Eur. Heart J. (2004) 25 371 376.
42. Chong A.Y., Blann A.D., Patel J., Freestone B., Hughes E., Lip G.Y. Endothelial dysfunction and damage in congestive heart failure: relation of flow-mediated dilation to circulating endothelial cells, plasma indexes of endothelial damage, and brain natriuretic peptide. Circulation (2004) 110 1794 1798.
43. Di Tullio M.R., Homma S., Jin Z., Sacco R.L. Aortic atherosclerosis, hypercoagulability, and stroke the APRIS (Aortic Plaque and Risk of Ischemic Stroke) study. J. Am. Coll. Cardiol. (2008) 52 855 861.
44. Meltzer R.S., Visser C.A., Fuster V. Intracardiac thrombi and systemic embolism. Ann. Intern. Med. (1986) 104 689 698.
45. Nixon J.V. Left ventricular mural thrombus. Arch. Intern. Med. (1983) 143 1567 1571.
46. Gibbs C.R., Blann A.D., Watson R.D., Lip G.Y.H. Abnormalities of hemorheological, endothelial and platelet function in patients with chronic heart failure in sinus rhythm. Circulation (2001) 103 1746 1751.
47. Jafri S.M., Ozawz T., Mammen E., Levine T.B., Johnson C., Goldstein S. Platelet Function, thrombin and fibrinolytic activity in patients with heart failure. Eur. Heart J. (1993) 14 205 212.
48. Yamamoto K., Ikeda U., Furuhashi K., Irokawa M., Nakayama T., Shimada K. The coagulation system is activated in idiopathic cardiomyopathy. J. Am. Coll. Cardiol. (1995) 26 1757 1758.
49. Chung I., Lip G.Y.H. Platelets and heart failure. Eur. Heart J. (2006) 27 2623 2631.
50. Chin B.S., Chung N.A., Gibbs C.R., Blann A.D., Lip G.Y.H. Vascular endothelial growth factor and soluble P-selectin in acute and chronic chronic heart failure. Am. J. Cardiol. (2002) 90 1258 1260.
51. Mehta J., Mehta P. Platelet function studies in heart disease. VI. Enhanced platelet aggregate formation activity in chronic heart failure: inhibition by sodium nitroprusside. Circulation (1979) 60 497 503.
52. Erne P., Wradle J., Sanders K., Lewis S.M., Maseri A. Mean platelet volume and size distribution and their sensitivity to agonist in patients with coronary artery disease and chronic heart failure. Thromb. Haemost. (1988) 59 259 263.
53. O'Connor C.M., Gurbel P.A., Serebruany V.L. Usefulness of soluble and surface bound P-selectin in detecting heightened platelet activity in patients with chronic heart failure. Am. J. Cardiol. (1999) 83 1345 1349.
54. Stumpf C., Lehner C., Eskafi S. et al. Enhanced levels of CD154 (CD40 ligand) on platelets in patients with chronic heart failure. Eur. J. Heart Fail. (2003) 5 629 637.
55. Chin B.S.P., Blann A.D., Gibbs C.R., Chung N.A.Y., Conway D.G., Lip G.Y.H. Prognostic value of interleukin-6, plasma viscosity, fibrinogen, von Willebrand factor, tissue factor and vascular endothelial growth factor levels in congestive heart failure. Eur. J. Clin. Invest. (2003) 33 941 948.
56. Cohn J.N. Left ventricle and arteries: structure, function, hormones and disease. Hypertension (2001) 37 346 349.
57. Sbarouni E., Bradshaw A., Andreotti F., Tuddenham E., Oakley C.M., Cleland J.G. Relationship between haemostatic abnormalities and neuroendocrine activity in heart failure. Am. Heart J. (1994) 127 607 612.
58. Kubo S.H., Rector T.S., Banks A.J., Williams R.E., Heifetz S.M. Endothelium-dependent vasodilatation is attenuated in patients with heart failure. Circulation (1991) 84 1589 1596.
59. Lip G.Y.H., Lowe G.D.O., Metcalfe M.J., Rumley A., Dunn F.G. Effects of warfarin therapy on plasma fibrinogen, von-willebrand factor and fibrin d-dimer in left ventricular dysfunction secondary to coronary artery disease with and without aneurysms. Am. J. Caridiol. (1995) 76 453 458.
60. Davis C.J., Gurbel P.A., Gatties W.A. et al. Haemostatic abnormalities in patients with chronic heart failure: diagnostic significance and clinical challenge. Int. J. Cardiol. (2000) 75 15 21.
61. Chong A.Y., Freestone B., Patel J. et al. Endothelial activation, dysfunction and damage in chronic heart failure and the relation to brain natriuretic peptide and outcomes. Am. J. Cardiol. (2006) 97 671 675.
62. Fischer D., Rossa S., Landmesser U. et al. Endothelial dysfunction in patients with chronic heart failure is independently associated with increased incidence of hospitalization, cardiac transplantation, or death. Eur. Heart J. (2005) 26 65 69.
63. Weber K.T., Sun Y., Tyagi S.C., Cleutjens J.P. Collagen network of the myocardium: function, structural remodelling and regulatory mechanisms. J. Mol. Cell. Cardiol. (1994) 26 279 292.
64. Tyagi S.C., Kumar S.G., Hass S.J. et al. Post-transcriptional regulation of extracellular matrix Metalloproteinase in human heart end-stage failure secondary to ischemic cardiomyopathy. J. Mol. Cell. Cardiol. (1996) 28 1415 1428.
65. Spinale F.G., Coker M.L., Krombach S.R. et al. Matrix Metalloproteinase inhibition during the development of chronic heart failure: effects on left ventricular dimensions and function. Cir Res (1999) 85 364 376.
66. Thomas C.V., Coker M.L., Zellner J.L., Handy J.R., Crumbley A.J., Spinale F.G. Increased matrix metalloproteinase activity and selective up regulation in LV myocardium from patients with end stage dilated cardiomyopathy. Circulation (1998) 97 1708 1715.
67. Morishige K., Shimokawa H., Matsumoto Y. et al. Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo. Cardiovasc. Res. (2003) 57 572 585.
68. Habib F.M., Springall D.R., Davies G.J., Oakley C.M., Yacoub M.H., Polak J.M. Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet (1996) 347 1151 1155.
69. Munger M.A., Johnson B., Amber I.J., Callahan K.S., Gilbert E.M. Circulating concentrations of pro inflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol. (1996) 77 723 727.
70. Cugno M., Mari D., Meroni P.L. et al. Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation. Br. J. Haematol. (2004) 126 85 92.
71. The CONSENSUS Trial Study Group. Effect of Enalapril on mortality in severe chronic heart failure Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N. Engl. J. Med. (1987) 316 1429 1435.
72. Al-Khadra A.S., Salem D.N., Rand W.M., Udelson J.E., Smith J.J., Konstam M.A. Warfarin anticoagulation and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction. J. Am. Coll. Cardiol. (1998) 31 749 753.
73. Al-Khadra A.S., Salem D.N., Rand W.M., Udelson J.E., Smith J.J., Konstam M.A. Antiplatelet agents and survival: a cohort analysis from the Studies of Left Ventricular Dysfunction (SOLVD) trial. J. Am. Coll. Cardiol. (1998) 31 419 425.
74. Cleland J.G., Findlay I., Jafri S. et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomised trial comparing antithrombotic strategies for patients with heart failure. Am. Heart J. (2004) 148 157 164.
75. Massie B.M., Collins J.F., Ammon S.E. et al. Randomized trial of warfarin, aspirin, and clopidogrel in patients with chronic heart failure: the Warfarin and Antiplatelet Therapy in Chronic Heart Failure (WATCH) trial. Circulation (2009) 119 1616 1624.
76. Massie B.M., Krol W.F., Ammon S.E. et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J. Card. Fail. (2004) 10 101 112.
77. Cokkinos D.V., Haralabopoulos G.C., Kostis J.B., Toutouzas P.K., HELAS investigators. Efficacy of antithrombotic therapy in chronic heart failure: the HELAS study. Eur. J. Heart Fail. (2006) 8 428 432.
78. Cleland J.G., Ghosh J., Freemantle N. et al. Clinical trials update and cumulative meta-analyses from the American College of Cardiology: WATCH, SCD-HeFT, DINAMIT, CASINO, INSPIRE, STRATUS-US, RIO-Lipids and cardiac resynchronisation therapy in heart failure. Eur. J. Heart Fail. (2004) 6 501 508.
79. Nguyen K.N., Aursnes I., Kjekshus J. Interaction between enalapril and aspirin on mortality after acute myocardial infarction: subgroup analysis of the Cooperative New Scandinavian Enalapril Survival Study II (CONSENSUS II). Am. J. Cardiol. (1997) 79 115 119.
80. Guazzi M., Brambilla R., Reina G., Tumminello G., Guazzi M.D. Aspirin-angiotensin-converting enzyme inhibitor coadministration and mortality in patients with heart failure: a dose-related adverse effect of aspirin. Arch. Intern. Med. (2003) 163 1574 1579.
81. Teo K.K., Yusuf S., Pfeffer M. et al. Effects of long-term treatment with angiotensin-converting-enzyme inhibitors in the presence or absence of aspirin: a systematic review. Lancet (2002) 360 1037 1043.
82. Flather M.D., Yusuf S., Køber L. et al. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients. ACE-Inhibitor Myocardial Infarction Collaborative Group. Lancet (2000) 355 1575 1581.
83. Dagenais G.R., Pogue J., Fox K., Simoons M.L., Yusuf S. Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trials. Lancet (2006) 368 581 588.
84. Blais C. Jr., Drapeau G., Raymond P. et al. Contribution of angiotensin-converting enzyme to the cardiac metabolism of bradykinin: an interspecies study. Am. J. Physiol. (1997) 273 H2263 H2271.
85. Swartz S.L., Williams G.H., Hollenberg N.K., Levine L., Dluhy R.G., Moore T.J. Captopril-induced changes in prostaglandin production. Relationship to vascular responses in normal man. J. Clin. Invest. (1980) 65 1257 1264.
86. Packer M. Interaction of prostaglandins and angiotensin II in the modulation of renal function in chronic heart failure. Circulation (1988) 77 (Suppl. I) 64 73.
87. Zucker I.H., Chen J.S., Wang W. Renal sympathetic nerve and hemodynamic responses to captopril in conscious dogs: role of prostaglandins. Am. J. Physiol. (1991) 260 H260 H266.
88. Heesch C.M., Crandall E., Turbek J.A. Converting enzyme inhibitors cause pressure independent resetting of baroreflex control of sympathetic outflow. Am. J. Physiol. (1996) 270 R728 R737.
89. Villar I.C., Francis S., Webb A., Hobbs A.J., Ahluwalia A. Novel aspects of endothelium dependent regulation of vascular tone. Kidney Int. (2006) 70 840 853.
90. Hall D., Zeitler H., Rudolph W. Counteraction of the vasodilator effects of enalapril by aspirin in sever heart failure. J. Am. Coll. Cardiol. (1992) 20 1549 1555.
91. Sturrock P.M., Struthers A.D. Non-steroidal anti-inflammatory drugs and angiotensin converting enzyme inhibitors: a commonly prescribed combination with variable effects on renal function. Br. J. Clin. Pharmacol. (1993) 35 343 348.
92. Brooks P.M., Day R.O. Non-steroidal anti-inflammatory drugs differences and similarities. N. Engl. J. Med. (1991) 324 1716 1725.
93. Guazzi M., Marenzi G., Alimento M., Contini M., Agostoni P. Improvement of alveolar-capillary membrane diffusing capacity with enalapril in chronic heart failure and counteracting effect of aspirin. Circulation (1997) 95 1930 1936.
94. Guazzi M., Pontone G., Agostoni P. Aspirin worsens exercise performance and pulmonary gas exchange in patients with heart failure who are taking angiotensin-converting enzyme inhibitors. Am. Heart J. (1999) 38 254 260.
95. Kindsvater S., Leclerc K., Ward J. Effects of co administration of aspirin or clopidogrel on exercise resting in patients with heart failure receiving angiotensin-converting enzyme inhibitor. Am. J. Cardiol. (2003) 91 1350 1352.
96. Spaulding C., Charbonnier B., Cohen-Solal A. et al. Acute hemodynamic interaction of aspirin and ticlopidine with enalapril: results of a double-blind randomized comparative trial. Circulation (1998) 98 757 765.
97. Baur L.H., Schipperheyn J.J., van der Laarse A. et al. Combining salicylate and enalapril in patients with coronary artery disease and heart failure. Br Heart J. (1995) 73 227 236.
98. Griffiths G.C., Stragnell R., Levinson D.C., Moore F.J., Ware A.G. A Study of the beneficial effects of anticoagulant therapy in chronic heart failure. Ann. Intern. Med. (1952) 37 867 887.
99. Harvey W.P., Finch C.A. Dicumarol prophylaxis of thromboembolic disease in chronic heart failure. N. Engl. J. Med. (1950) 242 208 211.
100. Parkash R., Wee V., Gardner M.J. et al. The impact of warfarin use on clinical outcomes in atrial fibrillation: a population-based study. Can. J. Cardiol. (2007) 23 457 461.
101. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: stroke Prevention Atrial Fibrillation II Study. Lancet (1994) 343 687 691.
102. Van der Meer F.J., Rosendall F.R., Vandenbroucke J.P., Briet E. Bleeding complication in oral anticoagulant therapy. Arch. Intern. Med. (1993) 153 15557 15562.
103. Gitter M.J., Jaeger T.M., Petterson T.M., Gersh B.J., Silverstein M.D. Bleeding and thromboembolism during anticoagulant therapy: a population -based study in Rochester, Minnesota. Mayo Clin. Proc. (1995) 70 725 733.
104. Fihn S.D., Callahan C.M., Martin D.C., MaDonell M.B., Henikoff J.G., White R.H. The risk for and severity of bleeding complications in elderly patients treated with warfarin. Ann. Intern. Med. (1996) 124 970 979.
105. Copland M., Walker I., Tait R.C. Oral anticoagulation and haemorrhagic complications in an elderly population with atrial fibrillation. Arch. Intern. Med. (2001) 161 2125 2128.
106. Palareti G., Leali N., Coccheri S. et al. Bleeding complications of oral anticoagulant treatment: an inception-cohort, prospective collaborative study (ISCOAT). Italian Study on Complications of Oral Anticoagulant Therapy. Lancet (1996) 348 423 428.
107. Hart R.G., Halperin J.L., Pearce L.A. et al. Stroke Prevention in Atrial Fibrillation Investigators. Lessons from the Stroke prevention in atrial fibrillation trials. Ann. Intern. Med. (2003) 138 831 838.
108. Sam C., Massaro J.M., D'Agostino R.B. Sr. et al. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am. J. Cardiol. (2004) 94 947 951.
109. Hylek E.M., Evans-Molina C., Shea C., Henault L.E., Regan S. Major haemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation (2007) 115 2689 2696.
110. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high-risk patients. BMJ (2002) 324 71 86.
111. Hayden M., Pignone M., Phillips C., Murlow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann. Intern. Med. (2002) 136 161 172. (Pubitemid 34073943)
112. Antithrombotic Trialists' (ATT) Collaboration, Baigent C., Blackwell L. et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet (2009) 373 1849 1860.
113. Pullicino P., Thompson J.L., Barton B. et al. Warfarin versus aspirin in patients with reduced cardiac ejection fraction (WARCEF): rationale, objectives, and design. J. Card. Fail. (2006) 12 39 46.